TY - JOUR
T1 - Efficacy of folic acid supplementation in stroke prevention
T2 - a meta-analysis
AU - Wang, Xiaobin
AU - Qin, Xianhui
AU - Demirtas, Hakan
AU - Li, Jianping
AU - Mao, Guangyun
AU - Huo, Yong
AU - Sun, Ningling
AU - Liu, Lisheng
AU - Xu, Xiping
PY - 2007/6/2
Y1 - 2007/6/2
N2 - Background: The efficacy of treatments that lower homocysteine concentrations in reducing the risk of cardiovascular disease remains controversial. Our aim was to do a meta-analysis of relevant randomised trials to assess the efficacy of folic acid supplementation in the prevention of stroke. Methods: We collected data from eight randomised trials of folic acid that had stroke reported as one of the endpoints. Relative risk (RR) was used as a measure of the effect of folic acid supplementation on the risk of stroke with a random effect model. The analysis was further stratified by factors that could affect the treatment effects. Findings: Folic acid supplementation significantly reduced the risk of stroke by 18% (RR 0·82, 95% CI 0·68-1·00; p=0·045). In the stratified analyses, a greater beneficial effect was seen in those trials with a treatment duration of more than 36 months (0·71, 0·57-0·87; p=0·001), a decrease in the concentration of homocysteine of more than 20% (0·77, 0·63-0·94; p=0·012), no fortification or partly fortified grain (0·75, 0·62-0·91; p=0·003), and no history of stroke (0·75, 0·62-0·90; p=0·002). In the corresponding comparison groups, the estimated RRs were attenuated and insignificant. Interpretation: Our findings indicate that folic acid supplementation can effectively reduce the risk of stroke in primary prevention.
AB - Background: The efficacy of treatments that lower homocysteine concentrations in reducing the risk of cardiovascular disease remains controversial. Our aim was to do a meta-analysis of relevant randomised trials to assess the efficacy of folic acid supplementation in the prevention of stroke. Methods: We collected data from eight randomised trials of folic acid that had stroke reported as one of the endpoints. Relative risk (RR) was used as a measure of the effect of folic acid supplementation on the risk of stroke with a random effect model. The analysis was further stratified by factors that could affect the treatment effects. Findings: Folic acid supplementation significantly reduced the risk of stroke by 18% (RR 0·82, 95% CI 0·68-1·00; p=0·045). In the stratified analyses, a greater beneficial effect was seen in those trials with a treatment duration of more than 36 months (0·71, 0·57-0·87; p=0·001), a decrease in the concentration of homocysteine of more than 20% (0·77, 0·63-0·94; p=0·012), no fortification or partly fortified grain (0·75, 0·62-0·91; p=0·003), and no history of stroke (0·75, 0·62-0·90; p=0·002). In the corresponding comparison groups, the estimated RRs were attenuated and insignificant. Interpretation: Our findings indicate that folic acid supplementation can effectively reduce the risk of stroke in primary prevention.
UR - http://www.scopus.com/inward/record.url?scp=34249730020&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34249730020&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(07)60854-X
DO - 10.1016/S0140-6736(07)60854-X
M3 - Article
C2 - 17544768
AN - SCOPUS:34249730020
SN - 0140-6736
VL - 369
SP - 1876
EP - 1882
JO - Lancet
JF - Lancet
IS - 9576
ER -